Mar 1 |
Vyne Therapeutics files for $250M mixed shelf
|
Feb 29 |
Recap: VYNE Therapeutics Q4 Earnings
|
Feb 29 |
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
|
Feb 27 |
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
|
Feb 21 |
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
|
Feb 2 |
Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock
|
Jan 16 |
Top 4 Health Care Stocks That May Rocket Higher In Q1
|
Jan 11 |
Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
|
Jan 10 |
Vyne reports positive data from Phase 1b study for vitiligo drug
|
Jan 10 |
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
|